Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
- Conditions
- Interventions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 32
- Registration Number
- NCT01322386
Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- St. John Health System, Michigan
- Target Recruit Count
- 11
- Registration Number
- NCT01287832
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
- Conditions
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 256
- Registration Number
- NCT01283581
- Locations
- 🇺🇸
University of South Alabama Medical Center, Mobile, Alabama, United States
🇺🇸Southbay Pharma Research, Buena Park, California, United States
🇺🇸Drug Research and Analysis Corp, Montgomery, Alabama, United States
Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
- Conditions
- Interventions
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 81
- Registration Number
- NCT01226992
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Actelion
- Target Recruit Count
- 84
- Registration Number
- NCT01222702
- Locations
- 🇨🇦
Clinical Investigative Site 6601, Montreal, Quebec, Canada
🇺🇸Clinical Investigative Site 6935, Marietta, Georgia, United States
🇸🇪Clinical Investigative Site 6702, Orebro, Sweden
Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Ruhr University of Bochum
- Target Recruit Count
- 1
- Registration Number
- NCT01199783
- Locations
- 🇩🇪
Herz- und Diabeteszentrum, Bad Oeynhausen, Germany
Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 178
- Registration Number
- NCT01198509
- Locations
- 🇺🇸
NYU Hospital for Joint Diseases, New York, New York, United States
🇺🇸Bellevue Hospital, New York, New York, United States
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Mountain Home Research & Education Corporation
- Target Recruit Count
- 28
- Registration Number
- NCT01196169
- Locations
- 🇺🇸
Johnson City Medical Center, Johnson City, Tennessee, United States
🇺🇸James H Quillen VA Medical Center, Mountain Home, Tennessee, United States
Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Duke University
- Target Recruit Count
- 509
- Registration Number
- NCT01191840
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸David Geffen School of Medicine UCLA, Los Angeles, California, United States
🇺🇸University of Colorado, Denver, Colorado, United States
Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting
- Conditions
- Interventions
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2018-12-26
- Target Recruit Count
- 80
- Registration Number
- NCT01175707
- Locations
- 🇺🇸
Heartland I.V. Care, Pittsburgh, Pennsylvania, United States
🇺🇸NationsMed Clinical Research, Inc., Stafford, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.